Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Intranasal Esketamine With/Without Nasal Guide
NCT02060929Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2013
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of esketamine in major depressive disorder (MDD) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration, Time to Reach Maximum Observed Plasma Concentration and 9 more. Started Oct 2013; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02060929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02060929.